PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES- A UK NHS PERSPECTIVE

May 1, 2005, 00:00
10.1016/S1098-3015(10)62911-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)62911-7/fulltext
Title : PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES- A UK NHS PERSPECTIVE
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)62911-7&doi=10.1016/S1098-3015(10)62911-7
First page :
Section Title :
Open access? : No
Section Order : 350
Categories :
Tags :
Regions :
ViH Article Tags :